2017 Is Banner Year for Drug Approvals by the Food and Drug Administration

被引：2
|
作者：
Ebied, Alex M. [1 ]
Cooper-DeHoff, Rhonda M. [1 ]
机构：
[1] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL USA
来源：
AMERICAN JOURNAL OF MEDICINE | 2018年 / 131卷 / 09期
关键词：
Accelerated approval; Fast track; FDA; New indication; Novel drugs; Priority review;
D O I：
10.1016/j.amjmed.2018.02.034
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In 2017. the US Food and Drug Administration approved 46 novel drugs, and 29 drugs received newly approved indications. This record setting year was due in part to the new expedited review pathways. A review of these drugs is summarized. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码：1025 / 1033
页数：9
相关论文
共 50 条
  • [21] USE OF EXTERNAL CONTROL ARMS IN NOVEL DRUG APPROVALS BY US FOOD AND DRUG ADMINISTRATION: A TARGETED REVIEW
    Gupta, P.
    Kumar, J.
    Shaikh, J.
    VALUE IN HEALTH, 2024, 27 (06) : S204 - S204
  • [22] Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019
    Dhodapkar, Meera
    Zhang, Audrey D.
    Puthumana, Jeremy
    Downing, Nicholas S.
    Shah, Nilay D.
    Ross, Joseph S.
    JAMA NETWORK OPEN, 2021, 4 (06)
  • [23] New US Food and Drug Administration Approvals Decrease Generic Flucytosine Costs
    Rajasingham, Radha
    Boulware, David R.
    CLINICAL INFECTIOUS DISEASES, 2019, 69 (04) : 732 - 732
  • [24] Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration
    Puthumana, Jeremy
    Egilman, Alexander C.
    Zhang, Audrey D.
    Schwartz, Jason L.
    Ross, Joseph S.
    JAMA INTERNAL MEDICINE, 2021, 181 (04) : 559 - 560
  • [25] POLICY DEBATE: The US food and drug administration and new drug approvals: A safety vs. innovation paradox?
    Hemphill, Thomas A.
    INNOVATION-MANAGEMENT POLICY & PRACTICE, 2013, 15 (03): : 364 - 367
  • [26] Investigating Rates of Food and Drug Administration Approvals and Guidances in Drug Development: A Structural Breakpoint/Cointegration Timeseries Analysis
    Iraj Daizadeh
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 1056 - 1067
  • [27] NOVEL DRUG APPROVALS BY THE US FOOD AND DRUG ADMINISTRATION IN RARE DISEASES: FINDINGS FROM 2020-2023
    Dubey, A.
    Gupta, P.
    Ranjan, N.
    Ray, P.
    Kumar, J.
    Shaikh, J.
    VALUE IN HEALTH, 2024, 27 (06) : S216 - S216
  • [28] Investigating Rates of Food and Drug Administration Approvals and Guidances in Drug Development: A Structural Breakpoint/Cointegration Timeseries Analysis
    Daizadeh, Iraj
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (05) : 1056 - 1067
  • [29] Assessing drug lag in new drug approvals by the Iran Food and Drug Administration compared to the US FDA, EMA, and PMDA: A 20-year analysis (2001-2021)
    Alipour, Sama
    Parashkouhi, Sadra Nadimi
    Mojahedian, Mohammadmahdi
    Abbasian, Hadi
    MEDICINE, 2024, 103 (25)
  • [30] Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021
    Kandemir, Esin Aysel
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (01) : 191 - 207
12345